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Clinical Research 
Clinical Research fuses indistinguishably into quality improve-
ment. It is increasingly necessary because new medications 
and techniques are pouring down on us, with their potential for 
great harm as well as good. Dr Gilbert believed that every 
reflective health worker would constantly undertake research/ 
quality control if she or he were not overwhelmed by a crowded 
practice, and that part of the difficulty lies in being too busy to 
consider how it could be improved. Discovery, he believed, 
consists of seeing what everybody sees and thinking what 
nobody has thought. But it takes time to contemplate, and 
reinvent. 
Single case studies, such as this 1962 analysis of 1/osone as 
a cause of hepatitis, remain an important type of research that 
can be carried out by any thoughtful physician as part of the 
routine practice of medicine. Dr Gilbert's report almost single-
handedly stopped the indiscriminate use of a new antibiotic. 
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Erythromycin is derived from a strain of Streptomyces and 
belongs to the macrolide family of antibiotics which include 
triacetyloleandomycin. Erythromycin was introduced in 1952. 1 
Erythromycin propionate was introduced in September, 1958. 
Its lauryl sulfate salt has been named erythromycin estolate. The 
manufacturer estimates that some 15 million courses of therapy 
with this drug have been given since its introduction, with only 
33 cases of jaundice having been reported as directly or indi-
rectly attributable to the drug.2 
Kuder, in reviewing 20,525 cases, noted that erythromycin 
propionate caused some type of gastrointestinal symptomatology 
in 5.7% of patients, whereas the lauryl sulfate salt of this drug 
(erythromycin estolate) caused only 2% to have gastrointestinal 
symptoms constituted the major side effects, with nausea lead-
ing the list. No jaundice or hepatitis was reported in this series. 
He also observed that of 69 patients less than one month of age 
receiving the antibiotic, there were no side effects except for 
loose stools in 2. Reichelderfer and associates4 also observed 
that giving large amounts of erythromycin estolate to premature 
and newborn infants resulted in no significant side effects after 
several days of treatment. 
More recently, Kohlstaedt2 has received reports from physi-
cians noting hepatitis in 13 patients treated with erythromycin 
estolate. In the more carefully studied patients, it appeared to be 
hypersensitivity rather than a toxic reaction. The initial symp-
-
toms of hepatitis appeared between the lOth and 21st day of 
continuous therapy or after repeated courses of the drug. 
Robinson5 also noted similar hypersensitivity with hepatitis in 
approximately 12% of the patients who received triacetyl-
oleandomycin or erythromycin estolate for longer than 14 days. 
This reaction mimics viral hepatitis, cholecystitis, or pancreatitis, 
with midepigastric pain, vomiting, transaminase elevation, in-
creased direct-reacting bilirubin, and a negative or weakly 
positive turbidity test. In some instances, serum alkaline phos-
phatase was elevated. Liver biopsy in one patient showed 
periportal infiltration with lymphocytes, a few polymorpho-
nuclear leukocytes, and many eosinophils. Peripheral eosinophilia 
has been noted. It is of interest that hepatitis with jaundice had 
been previously reported in 3 of 82 patients receiving 
triacety !oleandomycin. 6 
Report of a Case 
A 46-year-old physician was seen on September 13, 1961, 
after having taken 750 mg of erythromycin estolate during the 
previous 12 hours. When examined at about midnight, she was 
acutely ill, with severe epigastric pain radiating through to the 
back and both shoulders. She believed she was experiencing a 
myocardial infarction, while I considered biliary colic or 
pancreatitis as the cause of the upper abdominal pain, vomiting, 
and right upper quadrant tenderness. Subsequent events proved 
us both wrong: her serum amylase, gallbladder visualization, 
and electrocardiogram were all normal. The packed cell volume 
(PCV) was 43 ml%; hemoglobin 13.5 gm; white blood cell count 
6,600 with 76% polymorphonuclear leukocytes, 18% lympho-
cytes, 2% eosinophils, 3% monocytes, and 1% stab cells. Uri-
nalysis was normal.The serum glutamic oxalacetic transami-
nase (SGOT) was moderately elevated to 350 units (normal40 
to 80 units), but the thymol turbidity was normal at 2.5 units. For 
the first4 days of hospitalization, the patient was miserable with 
persistent upper abdominal pain, vomiting, and anorexia. The 
afebrile course was interrupted on the third day of the illness by 
a fever of 1 02°F (39° C). This fever subsided within 24 hours, and 
she was discharged 9 days after admission, free of symptoms 
except for mild epigastric distress after meals and residual 
tenderness in the right upper quadrant on deep inspiration. 
Further history disclosed that hives had developed after the 
patient had received penicillin several years before, but that she 
had taken erythromycin sterate for 4 days in May, 1961, without 
incident. Three erythromycin estolate capsules had been taken 
on September 13, because of a tooth extraction that day. There 
was no other history of drug sensitivity, asthma, hay fever, or 
other know allergy (Fig 1). 
On October 31, 1961, she came into the office desperately ill, 
with fever of 104°F (40° C), chills, nausea, vomiting, and 
abdominal pain so severe that she could not tolerate abdominal 
palpatation until after injection of 100 mg of meperidine hydro-
chloride. This time she had taken one 25-mg capsule of erythro-
mycin estolate after further dental work and had noted abdomi-
nal pain at 3 hours, chills and fever at 8 hours, and vomiting at 
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10 hours after the single dose. She was extremely sick and noted 
a peculiar disturbance of color vision, with red, yellow, and 
green vertical bars, on closing her eyes. There was also an 
unusual sensation of tumbling vertigo, and for several days there 
was 
Comment 
persistent yellow tinting of the central visual field. She had 
continuous headache, upper abdominal pain, and repeated at-
tacks of vomiting for the past 3 days. During this period, 
intravenous fluids were required. Thirty-six hours after the 
onset, she became afebrile and remained so until discharge on 
November 4, 1961 (Fig 1). 
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Fig 1. -Patient's response to administration of erythromycin estolate. 
Laboratory studies performed during this second episode 
showed increased serum bilirubin, with total bilirubin of 2.4 
mg%, 1.1 mg% direct-reacting. The SGOT was elevated to 91 
units. There was a slight increase in the serum alkaline phos-
phatase to 4.7 Bodansky units. Blood studies revealed a drop in 
the hemoglobin, PCV, and (except for eosinophils) granulocyte, 
as compared to the values obtained 2 weeks previously (PCV 35 
ml%,; hemoglobin 11.9 gm; white blood cell count 4,700 with 
52% polymorphonuclear leukocytes, 33% lymphocytes, 6% 
eosinophils, and 9% monocytes). A radio-rose bengal test done 
4 days after onset of acute symptoms indicated moderate liver 
dysfunction without biliary tract obstruction. The radio dye 
flowed into the intestine readily. Urinalysis, including qualita-
tive tests for bile and urobilinogen, was normal. The thymol 
turbidity was 2 units. 
By November 7, 1961, one week after taking the capsule, the 
patient was asymptomatic except for acute iritis of the left eye 
and epigastric distress after meals. On November 18, she had no 
symptoms. Scratch tests with erythromycin as the base, stearate, 
estolate, and controls were negative at 1, 24, and 72 hours. The 
SGOT, serum bilirubin, and blood cell count were normal. The 
PCV was 38 mil% white blood cell count 5,600, with 56% 
polymorphonuclear leukocytes, 37% lymphocytes, and 7% eosi-
nophils, and the radio-rose bengal test continued to indicate very 
slight liver dysfunction with 56% retention in 20 min. 
On December 5, 1961, after having taken a small test dose of 
less than one-quarter of a 250-mg tablet of erythromycin sterate 
the night before, the patient took the remaining portion of the 
tablet. No unusual signs or symptoms developed and 24 hours 
later, all laboratory studies, including SGOT, and radio-rose 
bengal, were within normal limits. 
-
This 46-year-old physician tolerated a 4-day course of eryth-
romycin sterate in 1957 and a 5-day course of erythromycin 
estolate in May, 1961. Neither of these courses of treatment 
caused symptoms, but the latter almost certainly sensitized her, 
so that a challenge dose of the same preparation administered on 
2 subsequent occasions cause symptoms and signs of hepatitis 
within 12 hours of erythromycin ingestion. Her second chal-
lenge of only 250 mg of erythromycin estolate caused a much 
more severe illness than the first challenge of 750 mg. A final 
challenge of 250 mg of erythromycin sterate resulted in no 
clinical or laboratory evidence of hepatitis. 
This case is similar in most respects to the one recently 
reported by Johnson and Hall.7 In their patient, cholestatic 
hepatitis developed after 12 days of erythromycin estolate. 
Three challenges with the estolate reactivated signs and symp-
toms of hepatitis. A final challenge with erythromycin base 
failed to produce hepatitis. They concluded that drug allergy was 
the cause of the hepatitis. 
Although clinical jaundice develops in less than 5% of patients 
receiving macrolide ester antibiotics, routine sulfo-
bromophatalein (BSP) and SGOT determinations carried out on 
patients receiving triacetyloleandomycin for longer than 10 
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Fig 2.-Comparison of formulas of erythromycin estolate 
and triacetyloleandomycin. Asterisks indicate position of 
desosamine OH group in both antibiotics. 
days indicate that subclinical hepatitis develops in approxi-
mately 50% of patients receiving the drug. In 3 of 4 patients with 
abnormal liver function tests, elevated SGOT and elevated BSP 
values developed within 24 hours of a challenge dose of 
triacetyloleandomycin. These results were sufficient to cause 2 
drug companies reporting this high incidence of occult hepatitis 
to revise their brochures and suggest that their produ~ts not be 
used for longer than 10 days. 8·9 The significance of the challenge 
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dose producing hepatitis within 24 hours of administration has 
been almost overlooked, for there is no word of caution regard-
ing a second course of the antibiotic. As yet, no comparable 
studies with erythromycin estolate have been reported, but it is 
anticipated that the results will be similar. The appearance of 
cholestatic hepatitis in patients receiving the macrolide antibiot-
ics, triacetyloleandomycin and erythromycin estolate, is too 
much to expect coincidence. The parent molecules, oleandomycin 
phosphate and erythromycin, have not produced hepatitis. 
Triacetylation of oleandomycin phosphate and propionylation 
of erythromycin results in preparations that are more effective 
antibiotics. At the same time, the new compound acquires the 
capacity to cause hepatitis. 
On turning to the chemical formulas 10· 12 (Fig 2) in an attempt 
to explain the sensitization property (Fig 2) of the esterified 
molecules, it is observed that erythromycin and oleandomycin 
phosphate differ as to their macrocyclic lactone nuclei and one 
of their side-chain sugars. The second side-chain "sugar," 
desosamine, is the same in both antibiotics. When the molecular 
position marked with an asterisk is represented by a simple OH 
group in either antibiotic, hepatitis does not occur; nor does it 
occur when stearate is added proximal to the single nitrogen 
atom in desoamine. 
Only when the OH at the positions marked by asterisks is 
replaced by the propionyl radical in erythromycin and by the 
acetyl radical in oleandomycin phosphate do these macrolide 
antibiotics acquire the capacity to cause hepatitis. In all prob-
ability, other acids similarly linked to macrolide desosamine 
would provoke similar hypersensitivity and hepatitis, but with 
the specificity of the immune response residing in the specific 
acid radical. 13 
It has been suggested14 that esterification at the molecular 
position indicated confers the properties of a haptene on the 
macrolide molecule. This chemical alteration may permit the 
antibiotic to become antigenic by enabling it to conjugate with 
the necessary body protein, or more likely provides the signal by 
which the individual's cellular clones recognize the antibiotic as 
"not self." In any event, administration of the esterified antibi-
otic to a susceptible individual starts the chain of events that may 
lead to the hypersensitivity response. Once this occurs, all that 
is now necessary to produce cholestatic hepatitis is a properly 
timed triggering dose of the antibiotic in the primed hypersen-
sitive individual. 
Summary 
The macrolide antibiotics erythromycin and oleandomycin, 
incapable of causing hepatitis in their basic form, apparently 
acquire this capacity by esterification of their desosamine side 
chains. 
Although abnormal liver function developed in approximately 
50% of patients receiving triacetyloleandomycin for longer than 
10 days, clinical jaundice developed in less than 5%. Because of 
the high incidence ofliver function abnormalities following the 
use oftriacetyloleandomycin, 2 drug firms have advised that this 
product not be used for longer than 10 days.lt appears advisable 
to observe similar precautions in the use of erythromycin estolate 
until appropriate investigation has excluded the possibility of 
high incidence of subclinical hepatitis. It is also suggested that 
a second course of either of these macrolide esters be used with 
extreme caution, if at all. 
I am grateful to my patient, Dr Emiko Sakurai Hirschy, who 
-
recognized the potential hazard of reexposure to the antibiotics 
studied, yet deliberately accepted the risk in order to gain more 
information about this hepatosensitivity. 
Generic and Trade Names of Drugs 
Triacetyloleandomycin - Cyclamycin, Tao. 
Erythromycin estolate - Ilosone. 
Erythromycin stearate - Erythocin Stearate. 
Meperidine hydrochloride - Demerol Hydrochloride. 
Oleandomycin phosphate - Matronycin. 
Erythromycin - Erythromycin, Ilotycin. 
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Combining patient information. The step beyond single 
case reports is to combine information from many patients in one 
or more practices. This is especially important if the answers 
vary in different practices, laboratories, or (so common in Ha-
waii) ethnic groups. The next papers describe the outcomes 
from some of the innumerable questions that cry out for solution, 
that would improve the health of our patients if known, and that 
can best be answered by ourselves. 
Dr Lynn Madanay tells this story about the following article: 
Several recent publications suggested that prostate-specific 
antigen (PSA) gradually increases with age in men without 
prostate cancer, and therefore laboratories should report age-
adjusted normal limits. Pressure was put on Lynn to consider 
changing the standards in his laboratory. He and Fred Gilbert 
were discussing whether to make those changes when Fred 
suggested that they find out whether the age-adjustments ob-
tained from mostly Whites at Mayo applied to our own laboratory 
and to our own ethnic populations. In three days Fred dropped 
on his desk a 16-page proposal, budget and all, ready for 
signature. A week later funds were available, and within three 
months the analysis was made, paper written, and presentation 
given at the American College of Physicians' Annual Scientific 
Meeting in April, 1995. 
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